Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trebananib - Amgen

Drug Profile

Trebananib - Amgen

Alternative Names: 20060439; AMG-386

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Dana-Farber Cancer Institute; Gynecologic Oncology Group; Merck Sharp & Dohme; National Cancer Institute (USA); Quantum Leap Healthcare Collaborative; Roswell Park Cancer Institute; Takeda
  • Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma

Most Recent Events

  • 07 Jul 2022 3683793=NCT01042379 trial removed from profile
  • 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
  • 09 Dec 2019 Amgen completes a phase II trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in the US, Canada, Australia, Belgium and India (NCT00479817)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top